The Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis is 5 Modulated by the Genetic Background
暂无分享,去创建一个
S. Borrell | J. Feldmann | S. Gagneux | Chloé Loiseau | L. Kamwela | Miriam Reinhard | Andrej Trauner | Rhastin A. D. Castro | Amanda Ross
[1] T. Clark,et al. Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance , 2019, BMC Genomics.
[2] John L. Johnson,et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis , 2018, Nature Medicine.
[3] T. Clark,et al. Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation , 2018, Science Advances.
[4] John L. Johnson,et al. Bacterial Factors That Predict Relapse after Tuberculosis Therapy , 2018, The New England journal of medicine.
[5] L. Rigouts,et al. Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development , 2018, bioRxiv.
[6] Alimuddin Zumla,et al. Accelerating the development of therapeutic strategies for drug-resistant tuberculosis , 2018, Nature Reviews Drug Discovery.
[7] S. Gagneux. Ecology and evolution of Mycobacterium tuberculosis , 2018, Nature Reviews Microbiology.
[8] Christian Beisel,et al. Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity , 2018, BMC Bioinformatics.
[9] E. Eugenin,et al. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum , 2017, Antimicrobial Agents and Chemotherapy.
[10] Antoine Frénoy,et al. Death and population dynamics affect mutation rate estimates and evolvability under stress in bacteria , 2017, bioRxiv.
[11] M. Murray,et al. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] M. Lamers,et al. High-fidelity DNA replication in Mycobacterium tuberculosis relies on a trinuclear zinc center , 2017, Nature Communications.
[13] D. Andersson,et al. Evolutionary Trajectories to Antibiotic Resistance. , 2017, Annual review of microbiology.
[14] Brendan Prideaux,et al. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach , 2017, PLoS Comput. Biol..
[15] A. Narechania,et al. Transmission of Extensively Drug‐Resistant Tuberculosis in South Africa , 2017, The New England journal of medicine.
[16] D. Hughes,et al. Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli , 2017, Molecular biology and evolution.
[17] Andrew Kitchen,et al. Armed conflict and population displacement as drivers of the evolution and dispersal of Mycobacterium tuberculosis , 2016, Proceedings of the National Academy of Sciences.
[18] S. Gandra,et al. Poverty and prevalence of antimicrobial resistance in invasive isolates. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[19] Liliana K. Rutaihwa,et al. Mycobacterium tuberculosis Lineage 4 comprises globally distributed and geographically restricted sublineages , 2016, Nature Genetics.
[20] R. MacLean,et al. Epistasis between antibiotic resistance mutations and genetic background shape the fitness effect of resistance across species of Pseudomonas , 2016, Proceedings of the Royal Society B: Biological Sciences.
[21] Xilin Zhao,et al. Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones , 2016, Nucleic acids research.
[22] P. de Rijk,et al. Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis , 2016, The Journal of antimicrobial chemotherapy.
[23] J. Berger,et al. Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from Mycobacterium tuberculosis , 2016, Proceedings of the National Academy of Sciences.
[24] N. Osheroff,et al. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase , 2016, Proceedings of the National Academy of Sciences.
[25] L. Rigouts,et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB , 2015, The Journal of antimicrobial chemotherapy.
[26] M. Chase,et al. DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader , 2015, Nature Genetics.
[27] Q. Zeng,et al. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa , 2015 .
[28] A. Crook,et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.
[29] P. Butcher,et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.
[30] V. Furió,et al. Testing the Role of Genetic Background in Parallel Evolution Using the Comparative Experimental Evolution of Antibiotic Resistance , 2014, Molecular biology and evolution.
[31] Jukka Corander,et al. Evolution and transmission of drug resistant tuberculosis in a Russian population , 2014, Nature Genetics.
[32] Jeffrey E. Barrick,et al. Genome dynamics during experimental evolution , 2013, Nature Reviews Genetics.
[33] Daniel C. Angst,et al. The cost of antibiotic resistance depends on evolutionary history in Escherichia coli , 2013, BMC Evolutionary Biology.
[34] Marc Lipsitch,et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.
[35] Marisa Klopper,et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis , 2013, Evolution, medicine, and public health.
[36] Benjamin Kerr,et al. Evolutionary rescue from extinction is contingent on a lower rate of environmental change , 2013, Nature.
[37] P. V. van Helden,et al. Putative Compensatory Mutations in the rpoC Gene of Rifampin-Resistant Mycobacterium tuberculosis Are Associated with Ongoing Transmission , 2012, Antimicrobial Agents and Chemotherapy.
[38] K. Mitruka,et al. Treatment Duration for Patients with Drug-Resistant Tuberculosis, United States , 2012, Emerging infectious diseases.
[39] Hansjakob Furrer,et al. Effect of Mutation and Genetic Background on Drug Resistance in Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.
[40] T. Sterling,et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. , 2012, The Journal of antimicrobial chemotherapy.
[41] S. Müller,et al. Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background , 2012, PLoS neglected tropical diseases.
[42] H. Takiff,et al. Current Prospects for the Fluoroquinolones as First-Line Tuberculosis Therapy , 2011, Antimicrobial Agents and Chemotherapy.
[43] Pia Abel zur Wiesch,et al. Population biological principles of drug-resistance evolution in infectious diseases. , 2011, The Lancet. Infectious diseases.
[44] M. Delarue,et al. Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase , 2010, PloS one.
[45] G. Kahlmeter,et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. , 2010, The Journal of antimicrobial chemotherapy.
[46] S. Borrell,et al. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[47] S. Niemann,et al. Sequence Analyses of Just Four Genes To Detect Extensively Drug-Resistant Mycobacterium tuberculosis Strains in Multidrug-Resistant Tuberculosis Patients Undergoing Treatment , 2009, Antimicrobial Agents and Chemotherapy.
[48] B. Levin,et al. Exploring the role of the immune response in preventing antibiotic resistance. , 2009, Journal of theoretical biology.
[49] Stefan Niemann,et al. High Functional Diversity in Mycobacterium tuberculosis Driven by Genetic Drift and Human Demography , 2008, PLoS biology.
[50] A. MacGowan,et al. Clinical implications of antimicrobial resistance for therapy. , 2008, The Journal of antimicrobial chemotherapy.
[51] C. D. Long,et al. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis , 2006, Science.
[52] Stefan Niemann,et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[53] Floyd E Romesberg,et al. Open access, freely available online PLoS BIOLOGY Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance , 2022 .
[54] S. Hoffner,et al. Drug-Susceptible Mycobacterium tuberculosis Beijing Genotype Does Not Develop Mutation-Conferred Resistance to Rifampin at an Elevated Rate , 2003, Journal of Clinical Microbiology.
[55] J. Musser,et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. , 2000, The Journal of infectious diseases.
[56] B. Barrell,et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.
[57] Robert H. Gilman,et al. Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay , 1998, Journal of Clinical Microbiology.
[58] B. D. de Jong,et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.
[59] Stefan Niemann,et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes , 2011 .
[60] Lurias,et al. MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .
[61] P. Foster,et al. Determining mutation rates in bacterial populations. , 2000, Methods.